Q-omics provides the consensus-scored SIK1B profile across patient tissues and cancer cell-line models. SIK1B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SIK1B is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, SIK1B RNA expression shows 15,138 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRP as cancer lineages where SIK1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIK1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIK1B survival associations across molecular data types. SIK1B RNA expression shows survival associations in the most cancer types (20), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIK1B RNA expression–survival associations across cancer types. High SIK1B expression shows unfavorable associations in ACC, PAAD, LUAD, KIRC, MESO and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SIK1B RNA expression.
This table summarizes SIK1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SIK1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIK1B shows lower tumor expression in KIRP, BRCA, KIRC, UCEC, LUSC and LIHC. The KIRP box plot shows higher SIK1B RNA expression in normal versus tumor tissue (log2 FC = −1.884, t-test p < 0.001).
This table shows molecular features associated with SIK1B in patient tissues and cancer cell lines. In patient samples, SIK1B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SIK1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
